ST. GEORGE, Utah and PALO ALTO, Calif., May 29, 2014—Intermountain Healthcare (an internationally recognized not-for-profit system of 22 hospitals, a medical group with over 185 physician clinics, and an affiliated health insurance company) and Syapse (the leading provider of software for bringing omics data into routine medical use) announced today a collaboration to bring genomics-driven precision cancer care to oncologists within the Intermountain system and also worldwide. This new clinical service, Intermountain Cancer Genomics, will provide cost-effective, genomics- driven, personalized treatment planning through easy-to-use software.
Intermountain Cancer Genomics is a comprehensive clinical service providing tumor genome profiling, analysis of genomic data from a molecular tumor board, targeted therapy options, drug procurement, and outcomes analysis. The service leverages Intermountain’s in-house infrastructure, which includes a clinical sequencing laboratory and an affiliated health insurance plan. The integrated service utilizes a molecular tumor board to develop treatment options from genomic testing results, in order to effectively procure targeted therapeutics. Quality-of-life issues also factor prominently in treatment plan development.
Syapse software will power Intermountain Cancer Genomics. Using Syapse’s web-based interface, oncologists will be able to order molecular tests, view genomic results and molecular tumor board interpretation, make a treatment selection, and order drugs targeted to a patient’s specific genomic makeup. Syapse software integrates data from multiple source systems to provide oncologists with a unified view of their patients’ clinical and genomics data, while also tracking patient outcomes.
“Most of the patients Intermountain Cancer Genomics has treated since inception have been successfully matched with targeted therapies, resulting in improved outcomes,” said Dr. Lincoln Nadauld, Director of Cancer Genomics at Intermountain Healthcare. “Software is critical for helping oncologists harness the power of complex genomics and clinical data, and we are excited to be working with Syapse.”
“At Syapse, we have built powerful technology to integrate genomic and clinical data to enable clinical decision making. We are excited to be collaborating with Intermountain to bring this technology to community oncologists worldwide,” said Jonathan Hirsch, Founder and President of Syapse.
For more information about Intermountain Cancer Genomics, please visit www.precisioncancercare.org.
About Intermountain Healthcare
Intermountain Healthcare is a Utah-based not-for-profit system of 22 hospitals, 185 clinics, a medical group with some 1,000 employed physicians, a health plans division called SelectHealth, and other health services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit www.intermountainhealthcare.org.
Syapse is disrupting healthcare by bringing omics into routine medical use. Syapse provides a precision medicine data platform to enable healthcare providers, laboratories, and registries to use molecular profiling to diagnose and treat patients. Led by an experienced, multidisciplinary team of entrepreneurs, software developers, and scientists, Syapse was founded at Stanford University and is backed by The Social+Capital Partnership. Syapse software is built on a semantic data platform and hosted on Amazon Web Services. For more information, please visit www.syapse.com.
For Intermountain Healthcare:
Terri Draper, (435) 251-2108
Andro Hsu, (650) 924-1461